Business Context and Reporting Period
This Form 8-K is filed by Mast Therapeutics, Inc. (not Savara Inc.) for the reporting period ending March 30, 2016. The company is a biopharmaceutical entity focused on the development of vepoloxamer for sickle cell disease and heart failure, and AIR001 for heart failure. The filing primarily addresses a change in independent registered public accounting firms and the adoption of a new executive incentive plan.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity for the current period. However, it notes that the prior year's audit report (ended December 31, 2015) included an emphasis-of-matter paragraph regarding the company's recurring significant operating losses and its need for additional financing to fund future operations.
Material Changes
- Change in Auditor: On March 30, 2016, the Audit Committee dismissed PricewaterhouseCoopers LLP (PwC) and engaged Mayer Hoffman McCann P.C. (MHM) as the independent registered public accounting firm for the fiscal year ending December 31, 2016.
- No Disagreements: The company confirmed there were no disagreements with PwC regarding accounting principles, financial statement disclosure, or auditing scope during the two most recent fiscal years or the interim period through March 30, 2016.
- Executive Compensation: The Board adopted the 2016 Executive Incentive Plan effective January 1, 2016, covering officers including the CEO, CFO, and SVP of Development.
Guidance, Outlook, and Risks
Management Commentary and Objectives: The 2016 Executive Incentive Plan outlines corporate performance objectives weighted as follows: 65% on research and development/regulatory affairs (specifically for vepoloxamer and AIR001), 20% on cash management and adequate capital, and 15% on increasing company value relative to peers.
Risks and Contingencies:
- The company faces recurring significant operating losses and requires additional financing.
- Executive awards are discretionary; the Board may abolish the plan or alter terms at any time without notice.
- Participants must remain continuously employed through the payment date (on or before March 14, 2017) to earn an award.
Investor Verification Checklist
- Verify the rationale for dismissing PwC and engaging MHM, despite the absence of reported disagreements.
- Confirm the company's current cash runway and specific plans for securing the "additional financing" noted in the prior audit report.
- Review the specific corporate performance metrics for R&D progress on vepoloxamer and AIR001 to assess the feasibility of the 65% weighted incentive target.
- Examine the full text of the 2016 Executive Incentive Plan (Exhibit 10.1) for detailed payout structures and individual performance criteria.